

1 **HIV coinfection is associated with low fitness *rpoB* variants in rifampicin-resistant**
2 ***Mycobacterium tuberculosis***

3

4 Chloé Loiseau^{a,b}, Daniela Brites^{a,b}, Miriam Reinhard^{a,b}, Kathrin Zürcher^c, Sonia Borrell^{a,b}, Marie
5 Ballif^c, Lukas Fenner^c, Helen Cox^d, Liliana K. Rutaihw^{a,b,e}, Robert J. Wilkinson^{f,g,h}, Marcel
6 Yotebiengⁱ, E Jane Carter^j, Alash'le Abimiku^k, Olivier Marcy^{l,m}, Eduardo Gotuzzoⁿ, Anchalee
7 Avihingsanon^o, Nicola Zetola^p, Basra Doulla^{q,r}, Erik C. Böttger^{s,t}, Matthias Egger^{c,u}, Sebastien
8 Gagneux^{a,b} #

9

10 ^aSwiss Tropical and Public Health Institute, Basel, Switzerland

11 ^bUniversity of Basel, Basel, Switzerland

12 ^cInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

13 ^dInstitute of Infectious Disease and Molecular Medicine and Wellcome Centre for Infectious Disease

14 Research in Africa, University of Cape Town, Cape Town, South Africa

15 ^eIfakara Health Institute, Bagamoyo, Tanzania

16 ^fWellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Observatory

17 7925, South Africa

18 ^gDepartment of Infectious Diseases, Imperial College London, London, UK

19 ^hFrancis Crick Institute, London NW1 1AT, UK

20

21 ⁱDivision of General Internal Medicine, Department of Medicine, Albert Einstein College of

22 Medicine, Bronx, NY, USA

23 ^jDepartment of Medicine, Moi University School of Medicine, and Moi Teaching and Referral

24 Hospital, Eldoret, Kenya

25 ^kInstitute of Human Virology, Abuja, Nigeria

26 ^lCentre de Prise en Charge de Recherche et de Formation, Yopougon, Abidjan, Côte d'Ivoire

27 ^mBordeaux Population Health Research Center, Inserm U1219, University of Bordeaux, Bordeaux,

28 France

^aTB Research Unit, Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.

^oThe HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Centre and Tuberculosis research unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

^pUniversity of Pennsylvania, Philadelphia, PA, USA

^qCentral Tuberculosis Reference Laboratory, Dar es Salaam, Tanzania

^rNational Tuberculosis and Leprosy Programme, Dar es Salaam, Tanzania

^sInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland

^tSwiss National Center for Mycobacteria, Zurich, Switzerland

^uCentre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

#Address correspondence to sebastien.gagneux@swisstph.ch

58 **Abstract**

59 We analysed 312 drug-resistant genomes of *Mycobacterium tuberculosis* (*Mtb*) collected from HIV
60 coinfecting and HIV negative TB patients from nine countries with a high tuberculosis burden. We
61 found that rifampicin-resistant *Mtb* strains isolated from HIV coinfecting patients carried
62 disproportionately more resistance-conferring mutations in *rpoB* that are associated with a low fitness
63 in the absence of the drug, suggesting these low fitness *rpoB* variants can thrive in the context of
64 reduced host immunity.

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83 Tuberculosis (TB), caused by members of the *Mycobacterium tuberculosis* (*Mtb*) Complex, is a
 84 leading cause of death worldwide, killing more people than any other infectious disease. Among the
 85 many factors driving the global TB epidemics, two factors stand out as particularly important:
 86 antibiotic resistance and HIV coinfection (1). Although the impact of both of these factors
 87 individually is well recognized, the interaction between them is less clear and likely depends on the
 88 particular epidemiologic setting (2). HIV coinfection and drug-resistant TB often coexist in severe
 89 epidemics, which could indicate spread of drug-resistant *Mtb* strains from immune-compromised
 90 patients (3–5). The propensity of drug-resistant *Mtb* strains to spread is influenced by the fitness cost
 91 associated with drug resistance determinants (6). Specifically, bacterial strains that have acquired drug
 92 resistance-conferring mutations may be less transmissible than their susceptible counterparts,
 93 although this fitness cost can be ameliorated by compensatory mutations (7–10). Moreover, the effect
 94 of different resistance-conferring mutations on fitness can be heterogeneous (11). In the clinical
 95 setting, there is a selection for high-fitness and/or compensated drug-resistant *Mtb* strains in TB
 96 patients (12). However, in immune-compromised hosts, such as HIV coinfecting patients, even strains
 97 with low-fitness resistance mutations might propagate efficiently (13–15), which could partially
 98 explain why drug-resistant TB has been associated with HIV co-infection (16, 17). However, to date,
 99 no evidence directly supports the notion that the immunological environment created by HIV co-
 100 infection modifies the fitness of drug-resistant *Mtb* (5, 18, 19).

101 In this study, we tested the hypothesis that resistance-conferring mutations with low fitness in *Mtb* are
 102 overrepresented among HIV-coinfecting TB patients. We focused our analysis on isoniazid and
 103 rifampicin, the two most important first-line anti-TB drugs, for which resistance-conferring mutations
 104 have been shown to differ in their fitness effects when measured in the laboratory (11). In addition,
 105 the frequency of the resistance alleles found in a clinical setting correlates well with the *in vitro*
 106 fitness of strains (20, 21). To explore the association between HIV coinfection and the fitness effect of
 107 different drug resistance-conferring mutations in *Mtb*, we compiled a collection of drug-resistant
 108 strains using the global International epidemiology Databases to Evaluate AIDS (IeDEA,
 109 <http://www.iedea.org>) consortium (22, 23) as a platform. For this study, 312 strains were collected

from HIV-coinfected and HIV uninfected TB patients originating from nine countries on three continents: Peru, Thailand, South Africa, Kenya, Côte d’Ivoire, Botswana, Democratic Republic of the Congo, Nigeria and Tanzania (supplemental methods, Figure 1 and supplemental Table S1). The association between the fitness of isoniazid resistance-conferring mutations and HIV coinfection was tested in a univariate analysis (Figure S1). Isoniazid resistance-conferring mutations were divided into three groups, as previously described (24): *katG* S315T mutation, *katG* mutations other than S315T, and *inhA* promoter mutations only. The S315T substitution in *katG* causes high-level isoniazid resistance, while retaining some catalase/peroxidase functions (25). Conversely, the *inhA* promoter mutation does not affect KatG activity. Other substitutions/deletions in *katG* have been associated with a lower fitness in the laboratory and are observed only rarely among clinical isolates (24, 26, 27). In the case of rifampicin, the association between the fitness of *rpoB* variants and HIV coinfection was tested in both a univariate and multivariate analysis (Table 1). Resistance-conferring variants in *rpoB* were classified into two groups based on their fitness effects documented previously (11, 28, 29). The mutation *rpoB* S450L was considered ‘high-fitness’, since this mutation was previously shown to confer a low fitness cost in the laboratory (11) and is generally the most common in clinical strains (30). Any other resistance-conferring mutation affecting *rpoB* was considered ‘low-fitness’ (11). The multivariable logistic regression model with outcome “low fitness *rpoB* variants” was adjusted for host-related factors (history of TB, country of isolation, sex and age) (31) and bacterial factors (*Mtb* lineage, presence of a *rpoA/C* compensatory mutation, clustering of the genome inferred by genetic relatedness). Seventy-six patients from Tanzania and Botswana were excluded from the model due to missing or unknown clinical data.

Out of 312 patients, 113 (36.2%) were HIV-coinfected, 120 (38.5%) were women, 115 (37%) were newly diagnosed TB cases (therefore treatment naïve), 276 (88.5%) harboured isoniazid resistance-conferring mutations, with or without additional resistance, and 282 (90.4%) harboured rifampicin resistance-conferring mutations, with or without additional resistance. In total, 78.8% (n= 246) of the strains were classified as being at least MDR, defined as resistance to isoniazid and rifampicin with or without additional resistance to 2nd line drugs. Amongst the 113 HIV coinfecting individuals, 34 (30%)

were on antiretroviral therapy (ART), 26 (23%) were not, and 53 (47%) had unknown ART start date. Four of the seven known *Mtb* lineages were represented in the following proportions: 11 L1 (3.5%), 57 L2 (18.3%), 38 L3 (12.2%), 206 L4 (66.0%). After dividing a total of 276 isoniazid-resistant strains into the three groups of isoniazid resistance-conferring mutations defined above, we found similar proportions in HIV-coinfected and HIV-uninfected patients (chi-square test, $p=0.54$, Figure S1), and as expected, the *katG* S315T mutation was the most frequent mutation in both categories (overall, found in 80% of isoniazid-resistant strains). In the case of rifampicin resistance, a univariate and multivariate analysis of 203 strains with complete clinical records, indicated that HIV coinfecting TB patients carried a higher proportion of low-fitness *rpoB* resistance variants in comparison to HIV negative patients (72.3% vs. 51.4%). The univariate analysis showed higher odds of having a low-fitness *rpoB* variant in HIV coinfecting patients (Odds Ratio 2.46 [95% Confidence Interval 1.30-4.66], $p=0.006$, Table 1). Our multivariable regression analysis confirmed these results and showed an association between low-fitness *rpoB* variants and HIV-coinfection, whilst controlling for other factors (Odds Ratio 4.58 [95% Confidence Interval 1.69, 12.44], $p=0.003$, Table 1). This association can be explained at least in two ways. Firstly, HIV-coinfected patients are thought to have fewer lung cavities on average and lower sputum bacillary load (32, 33). The resulting smaller *Mtb* population size would lead to fewer replication events, possibly reducing the number of mutations available for selection to act upon. In other words, low-fitness variants and high-fitness variants would co-occur less often in an HIV-coinfected patient, such that competition between them would be less likely. This scenario would be relevant for *de novo* acquisition of low-fitness drug-resistant variants within an HIV-coinfected patient. Secondly, following the transmission of a drug-resistant strain with low fitness to a host with reduced immunity, weaker immune pressure acting on this strain might lead to better bacterial survival. The association between low-fitness *rpoB* variants and HIV coinfection remained significant even after adjusting for the different epidemiologic settings (i.e. countries) and the strain genetic background (i.e. *Mtb* lineages). We also observed that strains carrying the *rpoB* S450L resistance-conferring mutation were more likely to also carry a compensatory mutation in *rpoA/C* (97.4% vs. 2.6%, Table 1). Even though this phenomenon seems counter-intuitive, it has been described multiple times (7, 9, 34–36) and might thus point to different mechanisms of compensation

in strains carrying resistance mutations other than *rpoB* S450L. In addition, in our study, L4 strains were associated with low fitness *rpoB* variants, compared to L2 (Odds Ratio 3.10 [95% Confidence Interval 0.94, 10.21], $p=0.06$, Table 1), indicating that the strain genetic background could play a role in shaping the cost of resistance, as was previously shown for other bacterial species (37) and for other drugs (38). In the regression analysis, we had several categorical variables with only few observations. Therefore, statistical power especially for country of isolation was low and the results should be interpreted with care.

HIV coinfecting TB patients are generally thought of having a reduced potential for TB transmission (32, 39) because these patients have reduced formation of lung cavities, more extrapulmonary disease, and a shorter period of infectiousness due to earlier diagnosis or higher mortality, especially in the absence of anti-retroviral treatment and if antibiotic resistance is already present (4). Based on the over-representation of low-fitness *rpoB* mutations in the context of HIV coinfection, one would expect a further reduction of the transmission potential of drug-resistant TB in this context. Yet, outbreaks of drug-resistant TB in HIV coinfecting patients have been reported (40). Such outbreaks might be explained by i) a higher risk of *Mtb* infection and reinfection due to diminished host immunity, ii) on-going transmission of drug-resistant *Mtb* from a larger pool of immune-competent TB patients to immune-compromised patients, iii) transmission occurring in conducive environments such as health care settings where both HIV coinfecting individuals and DR-TB patients are more likely to co-exist, and iv) *Mtb* strains carrying high-fitness drug resistance mutations.

In summary, using a global sample of drug-resistant *Mtb* clinical strains from HIV coinfecting and HIV negative TB patients, we showed that low-fitness *rpoB* variants were overrepresented in HIV coinfecting patients, and that this association was independent from other potential confounding factors. Taken together, our results provide new insights into how HIV coinfection can impact the fitness of drug-resistant *Mtb*.

Data availability. The *Mtb* whole-genome sequences from the patients are available on NCBI under several project IDs. The accession number for each genome is indicated in the supplemental Table 1.

Acknowledgments

We thank all the sites that participated in this study and the patients whose data were used in this study. We thank Dr. Jan Hattendorf for providing statistical help and Dr. Sebastian M. Gygli for critically reading the manuscript. Calculations were performed at the sciCORE (<http://scicore.unibas.ch/>) scientific computing core facility at University of Basel.

Funding

This research was supported by the Swiss National Science Foundation (grant numbers 153442, 310030_188888, 174281 and IZRJZ3_164171). The International Epidemiology Databases to Evaluate AIDS (IeDEA) is supported by the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases, the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, the Fogarty International Center, and the National Library of Medicine: Asia-Pacific, U01AI069907; CCASAnet, U01AI069923; Central Africa, U01AI096299; East Africa, U01AI069911; NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa, U01AI069919. Informatics resources are supported by the Harmonist project, R24AI124872. This work is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above. RJW is supported by Francis Crick Institute which receives funding from Wellcome (FC0010218), CRUK (FC0010218) and UKR1 (FC0010218). He is also supported by Wellcome (104803,203135).

References

1. World Health Organization. 2019. Global Tuberculosis Report.
2. Getahun H, Gunneberg C, Granich R, Nunn P. 2010. HIV Infection–Associated Tuberculosis: The Epidemiology and the Response. Clin Infect Dis 50:S201–S207.
3. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K.

219 2007. HIV Infection and Multidrug-Resistant Tuberculosis--The Perfect Storm. *J Infect Dis*
220 196:S86-107.

221 4. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J,
222 Friedland G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-
223 infected with tuberculosis and HIV in a rural area of South Africa. *Lancet* 368:1575–1580.

224 5. Eldholm V, Rieux A, Monteserin J, Lopez JM, Palmero D, Lopez B, Ritacco V, Didelot X,
225 Balloux F. 2016. Impact of HIV co-infection on the evolution and transmission of multidrug-
226 resistant tuberculosis. *Elife* 5:1–19.

227 6. Cohen T, Murray M. 2004. Modeling epidemics of multidrug-resistant *M. tuberculosis* of
228 heterogeneous fitness. *Nat Med* 10(10):1117–21.

229 7. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S,
230 Gagneux S. 2012. Whole-genome sequencing of rifampicin-resistant *Mycobacterium*
231 tuberculosis strains identifies compensatory mutations in RNA polymerase genes. *Nat Genet*
232 44:106–10.

233 8. Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, Harris SR, Bentley
234 SD, Parkhill J, Nejentsev S, Hoffner SE, Horstmann RD, Brown T, Drobniowski F. 2012.
235 Microevolution of extensively drug-resistant tuberculosis in Russia. *Genome Res* 22:735–45.

236 9. De Vos M, Müller B, Borrell S, Black PA, Van Helden PD, Warren RM, Gagneux S, Victor
237 TC. 2013. Putative compensatory mutations in the *rpoc* gene of rifampin-resistant
238 *mycobacterium tuberculosis* are associated with ongoing transmission. *Antimicrob Agents*
239 *Chemother* 57:827–832.

240 10. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Böttger EC. 2010. Directed
241 mutagenesis of *mycobacterium smegmatis* 16S rRNA to reconstruct the in vivo evolution of
242 aminoglycoside resistance in *mycobacterium tuberculosis*. *Mol Microbiol* 77:830–840.

243 11. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannon BJM. 2006. The
244 Competitive Cost of Antibiotic Resistance in *Mycobacterium tuberculosis*. *Science* (80-)
245 312:1944–1946.

246 12. Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, Pletschette M, Böttger EC.

247 2002. Fitness cost of chromosomal drug resistance-conferring mutations. *Antimicrob Agents*
248 *Chemother* 46:1204–1211.

249 13. Dye C, Williams BG, Espinal MA, Raviglione MC. 2002. Erasing the world’s slow stain:
250 strategies to beat multidrug-resistant tuberculosis. *Science* (80-) 295:2042–2046.

251 14. Cohen T, Dye C, Colijn C, Williams B, Murray M. 2009. Mathematical models of the
252 epidemiology and control of drug-resistant TB. *Expert Rev Respir Med* 3:67–79.

253 15. Borrell S, Gagneux S. 2009. Infectiousness, reproductive fitness and evolution of drug-
254 resistant *Mycobacterium tuberculosis*. *Int J Tuberc Lung Dis* 13:1456–1466.

255 16. Mesfin YM, Hailemariam D, Biadgign S, Kibret KT. 2014. Association between HIV/AIDS
256 and multi-drug resistance tuberculosis: A systematic review and meta-analysis. *PLoS One* 9:1–
257 9.

258 17. Suchindran S, Brouwer ES, Van Rie A. 2009. Is HIV infection a risk factor for multi-drug
259 resistant tuberculosis? A systematic review. *PLoS One* 4.

260 18. Khan PY, Yates TA, Osman M, Warren RM, van der Heijden Y, Padayatchi N, Nardell EA,
261 Moore D, Mathema B, Gandhi N, Eldholm V, Dheda K, Hesselning AC, Mizrahi V, Rustomjee
262 R, Pym A. 2019. Transmission of drug-resistant tuberculosis in HIV-endemic settings. *Lancet*
263 *Infect Dis* 19:e77–e88.

264 19. Ssengooba W, Lukoye D, Meehan CJ, Kateete DP, Joloba ML, De Jong BC, Cobelens FG,
265 Van Leth F. 2017. Tuberculosis resistance-conferring mutations with fitness cost among HIV-
266 positive individuals in Uganda. *Int J Tuberc Lung Dis* 21:531–536.

267 20. Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, Pletschette M, Böttger EC.
268 2002. Fitness cost of chromosomal drug resistance-conferring mutations. *Antimicrob Agents*
269 *Chemother* 46:1204–1211.

270 21. Billington OJ, Mchugh TD, Gillespie SH. 1999. Physiological cost of rifampin resistance
271 induced in vitro in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 43:1866–
272 1869.

273 22. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, Hartwell T,
274 Graber C, Chi BH, Boulle A, Dabis F, Wools-Kaloustian K. 2012. Cohort profile: The

275 international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. *Int J*
276 *Epidemiol* 41:1256–1264.

277 23. McGowan CC, Cahn P, Gotuzzo E, Padgett D, Pape JW, Wolff M, Schechter M, Masys DR.
278 2007. Cohort Profile: Caribbean, Central and South America Network for HIV research
279 (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate
280 AIDS (IeDEA) programme. *Int J Epidemiol* 36:969–976.

281 24. Gagneux S, Burgos M V., DeRiemer K, Enciso A, Muñoz S, Hopewell PC, Small PM, Pym
282 AS. 2006. Impact of bacterial genetics on the transmission of isoniazid-resistant
283 *Mycobacterium tuberculosis*. *PLoS Pathog* 2:0603–0610.

284 25. Pym AS, Saint-Joanis B, Cole ST. 2002. Effect of katG mutations on the virulence of
285 *Mycobacterium tuberculosis* and the implication for transmission in humans. *Infect Immun*
286 70:4955–4960.

287 26. Heym B, Alzari PM, Honore N, Cole ST. 1995. Missense mutations in the catalase-
288 peroxidase gene, katG, are associated with isoniazid resistance in *Mycobacterium tuberculosis*.
289 *Mol Microbiol* 15:235–245.

290 27. van Soolingen D, de Haas PEW, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. 2000.
291 Mutations at Amino Acid Position 315 of the katG Gene Are Associated with High-Level
292 Resistance to Isoniazid, Other Drug Resistance, and Successful Transmission of
293 *Mycobacterium tuberculosis* in The Netherlands . *J Infect Dis* 182:1788–1790.

294 28. Billington OJ, McHugh TD, Gillespie SH. 1999. Physiological cost of rifampin resistance
295 induced in vitro in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 43:1866–9.

296 29. Mariam DH, Mengistu Y, Hoffner SE, Andersson DI. 2004. Effect of rpoB Mutations
297 Conferring Rifampin Resistance on Fitness of *Mycobacterium tuberculosis*. *Antimicrob*
298 *Agents Chemother* 48:1289–1294.

299 30. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. 2009.
300 Tuberculosis drug resistance mutation database. *PLoS Med* 6:0132–0136.

301 31. Zürcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotebieng M,

302 Diero L, Carter EJ, Rockwood N, Wilkinson RJ, Cox H, Ezati N, Abimiku AG, Collantes J,
303 Avihingsanon A, Kawkitinarong K, Reinhard M, Hömke R, Huebner R, Gagneux S, Böttger
304 EC, Egger M. 2019. Drug susceptibility testing and mortality in patients treated for
305 tuberculosis in high-burden countries: a multicentre cohort study. *Lancet Infect Dis* 19:298–
306 307.

307 32. Kwan C, Ernst JD. 2011. HIV and tuberculosis: A deadly human syndemic. *Clin Microbiol*
308 *Rev* 24:351–376.

309 33. Hanrahan CF, Theron G, Bassett J, Dheda K, Scott L, Stevens W, Sanne I, Van Rie A. 2014.
310 Xpert MTB/RIF as a measure of sputum bacillary burden: Variation by HIV status and
311 immunosuppression. *Am J Respir Crit Care Med* 189:1426–1434.

312 34. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, Corander J,
313 Bryant J, Parkhill J, Nejentsev S, Horstmann RD, Brown T, Drobniewski F. 2014. Evolution
314 and transmission of drug-resistant tuberculosis in a Russian population. *Nat Genet* 46:279–
315 286.

316 35. Eldholm V, Monteserin J, Rieux A, Lopez B, Sobkowiak B, Ritacco V, Balloux F. 2015. Four
317 decades of transmission of a multidrug-resistant *Mycobacterium tuberculosis* outbreak strain.
318 *Nat Commun* 6:7119.

319 36. Song T, Park Y, Shamputa IC, Seo S, Lee SY, Jeon HS, Choi H, Lee M, Glynne RJ, Barnes
320 SW, Walker JR, Batalov S, Yusim K, Feng S, Tung CS, Theiler J, Via LE, Boshoff HIM,
321 Murakami KS, Korber B, Barry CE, Cho SN. 2014. Fitness costs of rifampicin resistance in
322 *Mycobacterium tuberculosis* are amplified under conditions of nutrient starvation and
323 compensated by mutation in the β' subunit of RNA polymerase. *Mol Microbiol* 91:1106–1119.

324 37. Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance
325 mutations and genetic background shape the fitness effect of resistance across species of
326 *Pseudomonas*. *Proceedings Biol Sci* 283.

327 38. Castro RAD, Ross A, Kamwela L, Reinhard M, Loiseau C, Feldmann J, Borrell S, Trauner A,
328 Gagneux S. 2019. The Genetic Background Modulates the Evolution of Fluoroquinolone-
329 Resistance in *Mycobacterium tuberculosis*. *Mol Biol Evol* 37:195–207.

39. Huang CC, Tchetgen ET, Becerra MC, Cohen T, Hughes KC, Zhang Z, Calderon R, Yataco R, Contreras C, Galea J, Lecca L, Murray M. 2014. The effect of HIV-related immunosuppression on the risk of tuberculosis transmission to household contacts. Clin Infect Dis 58:765–774.
40. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. 2007. HIV Infection and Multidrug-Resistant Tuberculosis—The Perfect Storm. J Infect Dis 196:S86–S107.

List of Tables and figures

Table 1. Results of the univariate and multivariate analysis showing host and bacterial factors associated with low fitness *rpoB* variants in 203 TB patients.

Figure 1. A. Frequency of *Mtb* lineages by HIV status for countries sampled. Countries coloured in grey were sampled. The barplots indicate the proportion of each lineage represented in this study. Magenta corresponds to *Mtb* lineage 1, blue corresponds to *Mtb* lineage 2, purple corresponds to *Mtb* lineage 3 and red corresponds to *Mtb* lineage 4. Solid colour corresponds to HIV negative and hatches correspond to HIV coinfecting TB patients. The number of genomes sampled in each country is indicated on top of the barplots. **B. Phylogenetic tree of the dataset used in the study.** Maximum likelihood phylogeny of 312 whole-genome sequences based on 18,531 variable positions. The scale bar indicates the number of substitutions per polymorphic site. The phylogeny was rooted on *M. canettii*. *Mtb* isolated from HIV coinfecting patients are indicated by black dots. The peripheral ring depicts the country of isolation of the strains sequenced.





Table 1. Results of the univariate and multivariate analysis showing host and bacterial factors associated with low fitness *rpoB* variants in 203 TB patients.

Dependent: fitness of <i>rpoB</i> variants		Low- fitness	High- fitness	univariable		multivariable	
				OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
HIV status	HIV-	71 (51.4)	67 (48.6)	reference		reference	
	HIV+	47 (72.3)	18 (27.7)	2.46 (1.30-4.66)	0.006	4.58 (1.69-12.44)	0.003
Presence of a compensatory mutation in <i>rpoA/C</i>	No	117 (71.3)	47 (28.7)	reference		reference	
	Yes	1 (2.6)	38 (97.4)	0.01 (0.00-0.08)	< 0.0001	0.01 (0.00-0.06)	< 0.0001
<i>Mtb</i> lineage	Lineage 2	16 (44.4)	20 (55.6)	reference		reference	
	Lineage 4	99 (61.5)	62 (38.5)	2.00 (0.96-4.14)	0.06	3.10 (0.94-10.21)	0.06
	Other (L1 or L3)	3 (50.0)	3 (50.0)	1.25 (0.22-7.05)	0.80	0.97 (0.11-8.31)	0.98
Clustering of the genome	No	109 (59.6)	74 (40.4)	reference		reference	
	Yes	9 (45.0)	11 (55.0)	0.56 (0.22-1.41)	0.21	1.05 (0.28-3.90)	0.94
Country of isolation	South Africa	29 (55.8)	23 (44.2)	reference		reference	
	Democratic Republic of Congo	11 (37.9)	18 (62.1)	0.48 (0.19-1.23)	0.13	0.39 (0.12-1.34)	0.14
	Côte d'Ivoire	35 (79.5)	9 (20.5)	3.08 (1.24-7.70)	0.02	2.04 (0.58-7.23)	0.27
	Kenya	4 (66.7)	2 (33.3)	1.59 (0.27-9.44)	0.61	0.94 (0.10-8.42)	0.96
	Nigeria	20 (58.8)	14 (41.2)	1.13 (0.47-2.72)	0.78	1.00 (0.29-3.40)	0.99
	Peru	16 (53.3)	14 (46.7)	0.91 (0.37-2.23)	0.83	1.49 (0.33-6.70)	0.60
	Thailand	3 (37.5)	5 (62.5)	0.48 (0.10-2.20)	0.34	0.42 (0.07-2.65)	0.36
Age	Mean (SD)	32.5 (10.4)	34.3 (12.3)	0.99 (0.96-1.01)	0.25	0.97 (0.94-1.01)	0.10
Sex	Female	47 (59.5)	32 (40.5)	reference			
	Male	71 (57.3)	53 (42.7)	0.91 (0.51-1.62)	0.75	0.77 (0.34-1.71)	0.52
History of TB disease	No	35 (52.2)	32 (47.8)	reference			
	Yes	83 (61.0)	53 (39.0)	1.43 (0.79-2.58)	0.23	0.96 (0.34-2.73)	0.94

Number of observations in model = 203; CI = confidence interval; The odds ratio and p-value are obtained from the regression model.